INVO Fertility Q2 Revenue Rises 17% as Clinic-Level Profitability Improves

INVO Fertility (NASDAQ:IVF) reported a 17% increase in second-quarter 2026 revenue to $2.18 million as the first full-quarter contribution from Family Beginnings and growth initiatives across its existing clinics expanded the fertility services platform.

Clinic-level Adjusted EBITDA increased to approximately $333,000 from $164,000 in Q1, but consolidated Adjusted EBITDA remained negative at $1.0 million, highlighting the gap between profitable clinic operations and the corporate costs associated with building a larger acquisition platform.

Key Investor Takeaways

• INVO Fertility (NASDAQ:IVF) increased Q2 revenue 17% to $2.18 million, while consolidated clinic revenue rose 18% to $2.17 million.
• Clinic-Level Adjusted EBITDA more than doubled sequentially to approximately $333,000 from $164,000 in Q1 2026.
• The company reported $0.9 million of net income, although the result included an approximately $2.5 million remeasurement gain related to the Birmingham acquisition.
• Adjusted EBITDA deteriorated to negative $1.0 million from negative $0.6 million a year earlier, showing that corporate-level profitability remains a challenge.
• INVO ended June with $3.7 million in cash and continues to evaluate acquisitions of established, profitable U.S. fertility clinics.

Why IVF Stock Is in Focus

Second-quarter revenue reached $2,175,485 compared with $1,863,654 a year earlier, driven primarily by the February 2026 acquisition of Indiana-based Family Beginnings.

Clinic revenue increased to $2,167,785 from $1,832,094. INVO also cited organic growth initiatives at Wisconsin Fertility Institute and its Georgia clinic as contributors to first-half performance.

The operating clinic platform generated approximately $333,000 of Adjusted EBITDA before corporate operating and public-company expenses. That compares with $164,000 during Q1 2026 and $951,000 for the full 2025 financial year.

At the consolidated level, however, Adjusted EBITDA was negative $1.0 million versus negative $0.6 million in Q2 2025.

INVO reported net income of approximately $0.9 million compared with a $3.6 million net loss a year earlier. The latest quarter benefited from an approximately $2.5 million gain from remeasuring its investment related to the Birmingham acquisition, while the prior-year period included roughly $2.1 million of discontinued-operation losses associated with NAYA Therapeutics.

Why This Matters for Investors

The results provide a clearer distinction between the underlying performance of INVO’s fertility clinics and the cost of operating and expanding the broader corporate platform.

Clinic-Level Adjusted EBITDA improved substantially from Q1, suggesting the operating businesses are generating positive earnings before the costs of corporate operations and maintaining a public company. Management’s strategy depends partly on increasing scale so those overhead costs can be spread across a larger revenue and earnings base.

Operating losses also narrowed. INVO recorded a loss from operations of approximately $1.3 million, compared with roughly $3.0 million in Q2 2025, while selling, general and administrative expenses declined to approximately $1.9 million from $2.2 million.

Cost of services increased to approximately $1.4 million from $1.1 million, reflecting the Family Beginnings acquisition and one-time staffing expenses at the Georgia clinic.

The June acquisition of the remaining interests in INVO’s Birmingham, Alabama fertility clinic adds another component to the growth strategy. Converting the business from a joint venture into a wholly owned subsidiary gives INVO operational control and full participation in its future economics.

Liquidity also improved, with cash reaching approximately $3.7 million at June 30 from approximately $2.1 million at the end of 2025.

What to Watch Next

INVO plans to pursue growth through two routes: increasing patient volumes and services within its existing clinics and acquiring established, profitable U.S. fertility practices.

The key financial question will be whether further clinic growth and acquisitions can increase Clinic-Level Adjusted EBITDA sufficiently to absorb corporate expenses and move consolidated Adjusted EBITDA toward profitability.

Investors can also monitor the integration and performance of Family Beginnings and the now wholly owned Birmingham clinic, alongside organic growth at the Wisconsin and Georgia operations.

INVO said it continues to evaluate a robust pipeline of potential U.S. fertility clinic acquisitions while investing in operations, finance and human resources infrastructure intended to support a larger network.

INVO Fertility stock price